StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.00−0.08 (-0.44%)

Close on Nov 17, 2026Market cap $2.88BP/E –Yield –

Denali Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Denali Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$542.70M. For fiscal 2025 it was -$555.34M. The highest annual figure on record is $62.72M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$555.34M–
FY2024Dec 31, 2024-$487.34M–
FY2023Dec 31, 2023-$196.70M–
FY2022Dec 31, 2022-$340.74M–
FY2021Dec 31, 2021-$295.75M-571.6%
FY2020Dec 31, 2020$62.72M–
FY2019Dec 31, 2019-$213.18M–
FY2018Dec 31, 2018-$46.37M–
FY2017Dec 31, 2017-$90.14M–
FY2016Dec 31, 2016-$87.43M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$130.54M–
Q1 FY2026Mar 31, 2026-$137.36M–
Q4 FY2025Dec 31, 2025-$137.37M–
Q3 FY2025Sep 30, 2025-$137.43M–
Q2 FY2025Jun 30, 2025-$134.96M–
Q1 FY2025Mar 31, 2025-$145.58M–
Q4 FY2024Dec 31, 2024-$129.85M–
Q3 FY2024Sep 30, 2024-$123.19M–
Q2 FY2024Jun 30, 2024-$116.59M-168.4%
Q1 FY2024Mar 31, 2024-$117.72M–
Q4 FY2023Dec 31, 2023-$132.57M–
Q3 FY2023Sep 30, 2023-$113.80M–
Q2 FY2023Jun 30, 2023$170.48M–
Q1 FY2023Mar 31, 2023-$120.82M–
Q4 FY2022Dec 31, 2022-$105.34M–
Q3 FY2022Sep 30, 2022-$107.49M–
Q2 FY2022Jun 30, 2022-$61.42M–
Q1 FY2022Mar 31, 2022-$66.50M–
Q4 FY2021Dec 31, 2021-$77.12M-131.6%
Q3 FY2021Sep 30, 2021-$85.59M–
Q2 FY2021Jun 30, 2021-$61.82M–
Q1 FY2021Mar 31, 2021-$71.22M–
Q4 FY2020Dec 31, 2020$244.08M–
Q3 FY2020Sep 30, 2020-$60.12M–
Q2 FY2020Jun 30, 2020-$61.28M–
Q1 FY2020Mar 31, 2020-$59.97M–
Q4 FY2019Dec 31, 2019-$57.76M-177.3%
Q3 FY2019Sep 30, 2019-$50.16M–
Q2 FY2019Jun 30, 2019-$62.76M–
Q1 FY2019Mar 31, 2019-$42.51M–
Q4 FY2018Dec 31, 2018$74.72M–
Q3 FY2018Sep 30, 2018-$37.96M–
Q2 FY2018Jun 30, 2018-$57.38M–
Q1 FY2018Mar 31, 2018-$25.75M–
Q4 FY2017Dec 31, 2017-$23.54M–
Q3 FY2017Sep 30, 2017-$22.29M–
Q2 FY2017Jun 30, 2017-$22.57M–
Q1 FY2017Mar 31, 2017-$21.74M–

More Denali Therapeutics figures

See a number that looks wrong?